Mohammad Luqman

USPTO Granted Patents = 7 (Patent Applications = 5)

CIPO Patents = 4 (Patent Applications = 5)

EPO Patents = 8 (Patent Applications = 11)

Average Co-Inventor Count = 3.9

ph-index = 5

Forward Citations = 216(Granted Patents)

Location History:

Emeryville, CA (US) (2011 - 2015)
Danville, CA (US) (2012 - 2015)

Company Filing History:

Novartis Vaccines & Diagnostics, Gmbh

patents

where one patent can have more than one assignee

Years Active: 2011-2015

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9005614 - PRLR-specific antibody and uses thereof (2015-04-14),

2. 8926979 - Treatment of cancer or pre-malignant conditions using anti-CD40 antibodies (2015-01-06),

3. 8637032 - Antagonist anti-CD40 monoclonal antibodies and methods for their use (2014-01-28),

4. 8337851 - Methods of monitoring the efficacy of anti-CD40 antibodies in treating a subject for a CD40-expressing cancer (2012-12-25),

5. 8333970 - Methods of monitoring the efficacy of anti-CD40 antibodies in treating a subject having an inflammatory or autoimmune disease (2012-12-18),

6. 8277810 - Antagonist anti-CD40 antibodies (2012-10-02),

7. 7867493 - PRLR-specific antibody and uses thereof (2011-01-11),

Title: Innovations by Inventor Mohammad Luqman

Introduction

Mohammad Luqman is a prominent inventor based in Danville, California, recognized for his significant contributions to medical science through his innovative patents. With a total of seven patents to his name, his work primarily focuses on the treatment of cancer and related conditions, utilizing targeted antibody therapies.

Latest Patents

Two of his latest patents showcase his advancement in cancer treatment methodologies. The first patent pertains to "PRLR-specific antibodies and uses thereof," which includes pharmaceutical compositions containing these antibodies. This invention is pivotal in the prevention and treatment of cancer, providing healthcare providers with a new therapeutic option. The second patent revolves around the "Treatment of cancer or pre-malignant conditions using anti-CD40 antibodies." This innovation offers methods to treat patients for cancers and pre-malignant conditions associated with CD40-expressing cells, particularly benefiting those who are resistant to alternative therapies such as rituximab (Rituxan®).

Career Highlights

Throughout his career, Mohammad Luqman has collaborated with reputable companies, including Novartis AG and Xoma Technology Ltd. His profound understanding of oncology and immunology has established him as a key player in the medical research field. His expertise is reflected in his innovative patents that address critical challenges in cancer treatment.

Collaborations

In his professional journey, Mohammad has worked alongside notable colleagues, including Sharon Lea Aukerman and Bahija Jallal. These collaborations have enriched his research and broadened the impact of his inventions in the field of cancer therapeutics.

Conclusion

Mohammad Luqman's inventive spirit and commitment to advancing cancer treatment through innovative antibody therapies underscore his important role in medical research. With several patents that hold great promise for patients with challenging conditions, his contributions continue to inspire progress in the fight against cancer. His legacy as an inventor not only enhances therapeutic options but also paves the way for future innovations in the healthcare industry.

This text is generated by artificial intelligence and may not be accurate.